European Heart Failure Guideline Updates: A Peer-to-Peer Discussion on SGLT-2 Inhibitors

Published: 10 September 2021

  • Views:

    Views Icon 824
  • Likes:

    Heart Icon 0

Overview

Full programme

  • Views:

    Views Icon 824
  • Likes:

    Heart Icon 0

Overview

SGLT-2 inhibitors represent one of the single biggest advances in heart failure practice. In the anticipated HF Guidelines, join Prof Andrew Coats and Prof Carolyn Lam in this peer-to-peer video, where we get a local interpretation and take a look back at the 2016 guidelines first and the move onto the 2021 ESC heart failure guideline updates and what this means for the use of SGLT-2 inhibitors in HFrEF. Specifically, we take a look at he evolution of the new guidance and how these should be adopted in future practice.

Supported by the Boehringer Ingelheim & Lilly Alliance

Series overview

Part 1

Where have we come from?

1 session

  • Where have we come from? Recap of 2016 Guidelines and Update on the 2021 ESC HF Guideline Recommendations for SGLT-2 Inhibitors

    Watch now

Part 2

Exploring the Clinical Data Behind Guideline Updates

1 session

  • Exploring the Clinical Data Behind Guideline Updates

    Watch now

Part 3

Real-world Practice with SGLT-2 Inhibitors

1 session

  • Real-world Practice with SGLT-2 Inhibitors

    Watch now

Faculty biographies